**MEETING MINUTES**

**Members Present:** Andris Antoniskis, MD, Tracy Klein, PhD, FNP; William Origer, MD; Stacy Ramirez, PharmD, Phillip Levine, PhD

**Members Present by Phone:** Joshua Bishop, PharmD; David Pass, MD

**Staff Present:** Roger Citron, RPh; Megan Herink, PharmD, BCPS; Ted Williams, PharmD; Valerie Smith; Richard Holsapple, RPh; Ralph Magrish, MPA; Israel Harden

**Staff Present by Phone:** Bing-Bing Liang, PharmD; Kathy Sentena, PharmD

**Audience:** David Bashoum (Genentech); Stacy Daw (Genentech); Amy Burns (OSU); Chelsea Smith (OSU); Lori Howarth (Bayer); Annie Ogostalick (Abbott); Steve Faloon (Otsoka); Paul Bonham (NovoNordisk); Treli Triantafillon (Viv HealthCare); Diann Matthews; Amanda Meeker (CareOregon); Yarli (CareOregon); Eric Meyer (Teva); Greg Crepta (Teva); Sherri Van Everen (Genentech); Deborah Wafer (Gilead); Yoona Kim (Gilead); Barry Benson (Merck); Nathan Wood (Merck); Bruce Smith (GSK); Cheryl Fletcher (Abbott); Gene McLauty (Viv); Jamie Damm (Vertex); Michael Estos (Pfizer); Rajesh Patel (BMS); Debra Edgar; Stephanie Kendall; Richard Kosesan

**NOTE:** Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff.

I. **CALL TO ORDER**
   a. The meeting was called to order at 1pm.
   b. Conflict of interest declarations were reviewed and no new conflicts were reported.
   c. The committee reviewed the June 28, 2012 minutes.

**ACTION:** All in favor to approve minutes as is.

II. **DUR ACTIVITIES**
   a. Mr. Magrish presented highlights from the FFY 2011 CMS Annual Report.
   b. Mr. Holsapple presented the ProDUR Report and the Committee recommended noticing pharmacies about the importance of identifying prescription fills that were canceled due to ProDUR denials.
   c. Dr. Williams presented the RetroDUR Report.
   d. Mr. Citron presented the Quarterly Utilization Reports.
   e. Dr. Sentena presented the Oregon State Drug Review Newsletter titled “Can The Diabetic War Be Fought By Aggressive Blood Pressure Control?”.

III. **OLD BUSINESS**
   a. Dr. Sentena presented on Oral Direct Factor X Inhibitors: Rivaroxaban (Xarelto®) recommending updates to the current prior authorization criteria.

**ACTION:** All in favor of criteria updates as is.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)
b. Dr. Herink presented on Targeted Immune Modulators recommending implementing prior authorization criteria for non-preferred agents only to ensure DMARDs are used first line, initiating quantity limits to prevent doses from exceeding recommendations and making Humira and Enbrel preferred on the PDL with no prior authorization requirements and Remicade and all other drugs in class non-preferred with prior authorization requirements.

*ACTION: All in favor after Executive Session of proposed PA criteria, PDL status updates and quantity limits.

c. Dr. Herink presented on Antipsoritics recommending updates to the prior authorization criteria.

*ACTION: All in favor of proposed PA criteria updates.

d. Dr. Herink presented on Fingolimod (Gilenya®) recommending updates to the prior authorization criteria.

*ACTION: All in favor of proposed PA criteria updates.

e. Dr. Herink presented on Erythropoiesis Stimulating Agents recommending updates to the prior authorization criteria, make Procrit and Aranesp preferred and Epogen and Peginesatide non-preferred.

*ACTION: All in favor after Executive Session of proposed PA criteria and PDL status updates.

IV. NEW BUSINESS

a. Dr. Herink presented on Inhaled Antibiotics and Dornase Alfa for Cystic Fibrosis recommending making tobramycin inhaled solution (Tobi) and dornase alfa (Pulmozyme) preferred with quantity limits and aztreonam inhalation solution (Cayston) non-preferred. Yoon Kim with Gilead presented public comment on the class. Expert testimony was submitted in writing by Dr. Jeff Gold, MD with the Department of Pulmonary Medicine at OHSU.

*ACTION: All in favor after Executive Session of making Tobi preferred with quantity limits, and make Cayston non-preferred with quantity limits. Pulmozyme (Dornase Alpha) was deferred until September’s meeting to discuss with hypertonic saline and percentage of patient’s tolerance and coverage guidance on vitamins.

b. Dr. Liang presented on ranolazine (Ranexa®) recommending making Ranexa® non-preferred.

*ACTION: All in favor after Executive Session of PDL status update.

c. Dr. Liang presented on Diuretic Agents Class recommending adding loop, thiazide/thiazide like and potassium sparing diuretics class to the PDL with all multisource agents ≤ $0.25 preferred, except for amiloride, chlorothiazide, chlorthalidone, eplerenone, ethycrinic acide, furosemide solution 40mg/5ml, methyclothiazide, metalozone, triamterent/HCTZ tablets.

*ACTION: All in favor after Executive Session of PDL status updates.


*ACTION: All in favor after Executive Session of PDL status updates.

e. Dr. Herink presented on Vascular Endothelial Growth Factors (VEGF) Inhibitors recommending making pegaptanib non-preferred and comparing costs for bevacizumab, ranibizumab and aflibercept.

*ACTION: All in favor after Executive Session to defer PDL updates until September’s meeting with updated pricing information.

V. The meeting adjourned at approximately 4pm.

*Agenda items will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)